Related Experiment Video
Updated: Jul 9, 2026
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution
Abstract:
Fibrosis is a major cause of mortality and morbidity worldwide with limited therapeutic options. Our understanding of fibrosis has significantly improved and led to the identification of "core" fibrogenic mechanisms that fuel a self-sustaining vicious cycle following the initial insult. The fibrotic niche is the result of complex cellular and molecular interactions that need to be disrupted to achieve transformational therapies. In this Review, we describe the current understanding of fibrogenic mechanisms, the progress and limitations of omics approaches in the identification of novel fibrotic pathways, and advances in therapeutic modalities that all together have the potential to unleash innovative cross-organ antifibrotic therapies.
Insights
Fibrosis, a global health issue, involves complex mechanisms driving a self-sustaining cycle. Disrupting this fibrotic niche offers potential for new cross-organ antifibrotic therapies.
Area of Science:
- * Fibrosis research
- * Cellular and molecular interactions
- * Therapeutic development
Background:
- * Fibrosis is a significant cause of global mortality and morbidity.
- * Limited therapeutic options exist for fibrotic diseases.
- * Understanding fibrotic mechanisms is crucial for developing effective treatments.
Purpose of the Study:
- * To review current knowledge of fibrogenic mechanisms.
- * To assess the role of omics approaches in identifying fibrotic pathways.
- * To explore advances in antifibrotic therapies.
Main Methods:
- * Comprehensive literature review of fibrotic mechanisms.
- * Analysis of omics approaches in fibrosis research.
- * Evaluation of current and emerging therapeutic modalities.
Main Results:
- * Identification of core fibrogenic mechanisms driving a self-sustaining cycle.
- * Progress and limitations of omics in discovering novel fibrotic pathways.
- * Advances in therapeutic strategies targeting fibrotic niches.
Conclusions:
- * Disrupting the complex fibrotic niche is key to developing transformative therapies.
- * Integrating mechanistic understanding, omics data, and therapeutic advances can foster cross-organ antifibrotic strategies.
- * Innovative therapies hold potential for treating diverse fibrotic conditions.
